CY1116545T1 - Οφθαλμικες συνθεσεις και μεθοδοι για τη θεραπευτικη αγωγη των οφθαλμων - Google Patents

Οφθαλμικες συνθεσεις και μεθοδοι για τη θεραπευτικη αγωγη των οφθαλμων

Info

Publication number
CY1116545T1
CY1116545T1 CY20151100661T CY151100661T CY1116545T1 CY 1116545 T1 CY1116545 T1 CY 1116545T1 CY 20151100661 T CY20151100661 T CY 20151100661T CY 151100661 T CY151100661 T CY 151100661T CY 1116545 T1 CY1116545 T1 CY 1116545T1
Authority
CY
Cyprus
Prior art keywords
methods
eyes
optical compositions
education
therapeutic
Prior art date
Application number
CY20151100661T
Other languages
English (en)
Inventor
Joseph G Vehige
Peter A Simmons
Joan-En Chang-Lin
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36218032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116545(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of CY1116545T1 publication Critical patent/CY1116545T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1732—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Οι οφθαλμικές συνθέσεις οι οποίες συμπεριλαμβάνουν συστατικά συμβατής διαλυμένης ουσίας και/ή πολυανιονικά συστατικά είναι χρήσιμες στην αγωγή των οφθαλμών, παραδείγματος χάριν για την ανακούφιση από το σύνδρομο της ξηροφθαλμίας, προκειμένου να προστατεύονται οι οφθαλμοί έναντι υπερτονικής προσβολής και/ή των αρνητικών επιδράσεων κατιονικών ειδών επί της οφθαλμικής επιφανείας των οφθαλμών και/ή προκειμένου να διευκολύνεται η αποθεραπεία μετά από χειρουργική επέμβαση στον οφθαλμό.
CY20151100661T 2004-11-16 2015-07-29 Οφθαλμικες συνθεσεις και μεθοδοι για τη θεραπευτικη αγωγη των οφθαλμων CY1116545T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/990,811 US8569367B2 (en) 2004-11-16 2004-11-16 Ophthalmic compositions and methods for treating eyes
EP20100185764 EP2422765B1 (en) 2004-11-16 2005-11-14 Ophthalmic compositions and methods for treating eyes

Publications (1)

Publication Number Publication Date
CY1116545T1 true CY1116545T1 (el) 2017-03-15

Family

ID=36218032

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20151100661T CY1116545T1 (el) 2004-11-16 2015-07-29 Οφθαλμικες συνθεσεις και μεθοδοι για τη θεραπευτικη αγωγη των οφθαλμων
CY20151101009T CY1116936T1 (el) 2004-11-16 2015-11-10 Οφθαλμικες συνθεσεις και μεθοδοι για τη θεραπευτικη αγωγη των οφθαλμων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20151101009T CY1116936T1 (el) 2004-11-16 2015-11-10 Οφθαλμικες συνθεσεις και μεθοδοι για τη θεραπευτικη αγωγη των οφθαλμων

Country Status (24)

Country Link
US (10) US8569367B2 (el)
EP (4) EP3777836A1 (el)
JP (1) JP5179880B2 (el)
KR (1) KR101344602B1 (el)
CN (1) CN101056618B (el)
AR (1) AR052031A1 (el)
AU (2) AU2005306721B2 (el)
BR (2) BR122019023144B8 (el)
CA (1) CA2588044C (el)
CY (2) CY1116545T1 (el)
DK (3) DK1811959T4 (el)
ES (3) ES2842226T3 (el)
HK (2) HK1107027A1 (el)
HU (2) HUE026575T2 (el)
IL (1) IL182532A (el)
NO (3) NO347855B1 (el)
NZ (2) NZ597106A (el)
PL (3) PL218364B1 (el)
PT (2) PT2422765E (el)
RU (1) RU2410081C2 (el)
SI (2) SI1811959T2 (el)
TW (1) TWI369996B (el)
WO (1) WO2006055454A2 (el)
ZA (1) ZA200702917B (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050147584A1 (en) * 2004-01-05 2005-07-07 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US7220422B2 (en) 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
TWI393567B (zh) * 2005-03-31 2013-04-21 Bausch & Lomb 治療乾眼之組合物及相關之製造方法及使用方法
TW200722109A (en) * 2005-03-31 2007-06-16 Bausch & Lomb Polysaccharide and polyol composition for treating dry eye and related methods of manufacture and methods of use
WO2007005421A2 (en) * 2005-07-01 2007-01-11 Bausch & Lomb Incorporated Long lasting alginate dry eye, related methods of manufacture and methods of use
KR101401353B1 (ko) * 2005-07-01 2014-05-29 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 점안약의 형태로 안구 사용을 위한 생리적 보조제 또는의약품의 제조를 위한 ｌ-카르니틴 또는 알카노일ｌ-카르니틴의 용도
CN1939534B (zh) * 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
DE102005055275A1 (de) * 2005-11-17 2007-05-24 Ursapharm Arzneimittel Gmbh & Co. Kg Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung
US20080057022A1 (en) * 2006-08-30 2008-03-06 Erning Xia Ophthalmic Pharmaceutical Compositions and Uses Thereof
US20080095754A1 (en) * 2006-10-18 2008-04-24 Burke Susan E Ophthalmic compositions comprising diglycine
US8138156B2 (en) 2006-10-18 2012-03-20 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US8158679B2 (en) * 2006-12-11 2012-04-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of L-carnitine for the preparation of a medicament in the form of eye-drops for treating corneal diseases
DE102006060953A1 (de) * 2006-12-12 2008-08-07 Farco-Pharma Gmbh Pharmazeutische Zubereitung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes
EP2101725A1 (en) * 2006-12-14 2009-09-23 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Use of l-carnitine or of alkanoyl l-carnitines for the preparation of a physiological supplement or medicament for ophthalmic use in the form of eye drops
US20080148689A1 (en) * 2006-12-20 2008-06-26 Bausch & Lomb Incorporated Packaging solutions
US8629099B2 (en) 2008-03-25 2014-01-14 Bausch & Lomb Incorporated Ophthalmic compositions comprising a dipeptide
CA2741288A1 (en) * 2008-10-20 2010-04-29 Allergan, Inc. Ophthalmic compositions useful for improving visual acuity
WO2010141648A2 (en) 2009-06-05 2010-12-09 Allergan, Inc. Artificial tears and therapeutic uses
ITMI20100319A1 (it) * 2010-02-26 2011-08-27 Lo Li Pharma Srl Composizioni comprendenti mioinositolo e il loro uso nel trattamento delle malattie respiratorie.
US9636355B2 (en) 2011-09-22 2017-05-02 Theo Holdings, Llc Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
IN2014CN04809A (el) * 2011-12-07 2015-09-18 Allergan Inc
CA2859997C (en) * 2011-12-23 2016-12-13 University Of Western Sydney Ophthalmic formulation
US8324171B1 (en) 2012-02-06 2012-12-04 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US8664180B2 (en) 2012-02-06 2014-03-04 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US10085960B2 (en) 2012-03-30 2018-10-02 Brien Holden Vision Institute Methods and compositions for reducing ocular discomfort
SI3517100T1 (sl) * 2013-02-01 2021-02-26 Allergan, Inc. Umetne solze, ki vsebujejo natrijev hialuronat in karboksimetilcelulozo
US9394355B2 (en) 2014-08-20 2016-07-19 Silk Technologies, Ltd. Fibroin-derived protein composition
EP3223794A1 (en) 2014-11-25 2017-10-04 Allergan, Inc. Stabilized omega-3 ophthalmic compositions
ITUB20153104A1 (it) * 2015-08-13 2017-02-13 Sooft Italia S P A Contrada Molino 17 68333 Montegiorgio Fm Composizione ed uso di collirio a base di inositolo per migliorare l'accomodazione visiva dei pazienti
EP3319538A4 (en) 2015-10-23 2018-10-03 The Trustees of Columbia University in the City of New York Laser induced collagen crosslinking in tissue
JP2019519596A (ja) 2016-04-08 2019-07-11 コーネル・ユニバーシティーCornell University シルク由来タンパク質を使用して創傷治癒を増進する方法
WO2017214604A1 (en) 2016-06-10 2017-12-14 The Trustees Of Columbia University In The City Of New York Devices, methods, and systems for detection of collagen tissue features
RU2623205C1 (ru) * 2016-07-13 2017-06-22 Станислав Анатольевич Кедик Офтальмологический гель таурина
KR102275012B1 (ko) 2016-08-12 2021-07-07 실크 테크놀로지스 리미티드 염증 치료용 실크 유래 단백질
US11666481B1 (en) 2017-12-01 2023-06-06 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of collagen-containing tissues
CN111467349B (zh) * 2020-05-14 2021-06-01 华熙生物科技股份有限公司 人工泪液及其制备方法
AU2022231886A1 (en) * 2021-03-10 2023-09-14 Bausch + Lomb Ireland Limited Contact lens treating solution
US12012238B2 (en) * 2021-05-26 2024-06-18 Bausch + Lomb Ireland Limited Packaging solutions
WO2023034993A1 (en) * 2021-09-03 2023-03-09 Gleich Gerald J Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1781701A (en) 1928-05-16 1930-11-18 Phillips Morris Godfrey Philip Machine for removing flags and other adhering leaf from the stalks of tobacco leaves
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
ATE6466T1 (de) 1979-10-26 1984-03-15 Smith And Nephew Associated Companies P.L.C. Autoklavierbare emulsionen.
WO1984004681A1 (en) * 1983-05-25 1984-12-06 Alcon Lab Inc Ophthalmic solution
JPS6436255A (en) * 1987-07-31 1989-02-07 Fujitsu Ltd Feeding circuit
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IT1235153B (it) 1988-11-15 1992-06-22 Sigma Tau Ind Farmaceuti Uso dell'acetil l-carnitina nel trattamento terapeutico della cataratta e composizioni farmaceutiche utili in tale trattamento
IT1224795B (it) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
DE436726T1 (de) 1989-08-03 1992-02-06 Eisai Co., Ltd., Tokio/Tokyo Verfahren zur photostabilisierung von augenspuelloesungen sowie photostabilisierte augenspuelloesung.
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (de) * 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
JP3431216B2 (ja) 1993-06-18 2003-07-28 千代田化工建設株式会社 触媒層支持構造
CA2199610A1 (en) 1994-09-14 1996-03-21 Taisho Pharmaceutical Co., Ltd. Eye drops for repairing repairing corneal damage
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US5847294A (en) * 1996-04-09 1998-12-08 Amherst Process Instruments, Inc. Apparatus for determining powder flowability
JPH1036255A (ja) 1996-07-24 1998-02-10 Nikken Chem Co Ltd 眼圧降下用点眼剤
IT1288399B1 (it) 1996-12-03 1998-09-22 Sigma Tau Ind Farmaceuti Medicamento per il trattamento terapeutico della maculopatia legata all'eta', della maculopatia non legata all'eta' e per la profilassi
FI106923B (fi) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6770675B2 (en) * 1997-03-17 2004-08-03 Novartis Ag Compositions and methods for reducing ocular hypertension
DE69833000T2 (de) 1997-09-26 2006-09-07 Noven Pharmaceuticals, Inc., Miami Bio-klebemittelzusammensetzungen
US6274725B1 (en) 1998-06-02 2001-08-14 Isis Pharmaceuticals, Inc. Activators for oligonucleotide synthesis
IT1302307B1 (it) * 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
DE69919379T2 (de) * 1998-11-13 2005-09-08 Continental Projects Ltd. Komplexe von hyaluronic saure/carnitinen und pharmazeutische und kosmetische zusammensetzungen
US6228392B1 (en) * 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
KR100354606B1 (ko) 2000-02-01 2002-09-30 주식회사 중외제약 다목적 콘택트 렌즈 관리 용액 조성물
DK2153819T3 (da) * 2000-07-14 2012-12-03 Allergan Inc Anvendelse af en opløselighedsforbedrende bestanddel i en vandig sammensætning omfattende brimonidintartrat
AU781975B2 (en) 2000-09-14 2005-06-23 Hayashibara Co., Ltd Pharmaceutical composition for ophthalmic use
US8557868B2 (en) 2000-11-04 2013-10-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions using low molecular weight amines
CA2428985C (en) 2000-11-08 2011-05-24 Bio-Concept Laboratories Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US20030069410A1 (en) 2001-06-14 2003-04-10 Isis Pharmaceuticals, Inc. Methods for preparing oligonucleotides having chiral phosphorothioate linkages
AR036122A1 (es) 2001-07-03 2004-08-11 Avecia Biotechnology Inc Un complejo de sal que comprende un n-alquilimidazol y una 1,1-dioxo-1,2-dihidro-1l6-benzo [d]-isotiazol-3-ona y un metodo para sintetizar oligonucleotidos utilizando la quimica de fosforamidita
US6936589B2 (en) 2001-09-28 2005-08-30 Albert T. Naito Parenteral delivery systems
US7045121B2 (en) * 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
US6858614B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
AU2003259145A1 (en) 2002-07-17 2004-02-02 Spencer P. Thornton Treatment for dry eye syndrome
JP2006504701A (ja) * 2002-09-30 2006-02-09 マーク・エー・バビザイェフ 眼疾患の局所的治療方法、並びに、その治療用組成物及び治療用手段
ITRM20020492A1 (it) 2002-10-01 2004-04-02 Sigma Tau Ind Farmaceuti Uso della propionil l-carnitina per la preparazione di un medicamento per il trattamento del glaucoma.
US20040137079A1 (en) 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
JPWO2004084877A1 (ja) * 2003-03-26 2006-06-29 株式会社メニコン 眼科用組成物
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
BRPI0808410A2 (pt) 2007-02-28 2015-06-23 Aciex Therapeutics Inc Métodos e composições para normalizar secreções da glândula meibomiana
JP4929245B2 (ja) 2008-07-31 2012-05-09 株式会社ベッセル工業 工具類のグリップ
WO2010141648A2 (en) 2009-06-05 2010-12-09 Allergan, Inc. Artificial tears and therapeutic uses
US9907826B2 (en) * 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Also Published As

Publication number Publication date
HUE026575T2 (en) 2016-06-28
SI1811959T2 (sl) 2022-10-28
IL182532A (en) 2013-10-31
ZA200702917B (en) 2008-09-25
PL2422765T3 (pl) 2015-10-30
EP1811959B1 (en) 2015-09-02
NZ583757A (en) 2011-11-25
CN101056618A (zh) 2007-10-17
CY1116936T1 (el) 2017-04-05
AU2005306721B2 (en) 2012-03-08
EP2952178B1 (en) 2020-09-02
ES2543974T3 (es) 2015-08-26
ES2842226T3 (es) 2021-07-13
NO20220060A1 (el) 2007-08-15
US8569370B2 (en) 2013-10-29
NZ597106A (en) 2013-06-28
EP3777836A1 (en) 2021-02-17
US9254324B2 (en) 2016-02-09
SI1811959T1 (sl) 2015-11-30
NO346214B1 (no) 2022-04-25
PT1811959E (pt) 2015-11-10
AU2012203398A1 (en) 2012-06-28
PL218364B1 (pl) 2014-11-28
RU2410081C2 (ru) 2011-01-27
HUE025116T2 (en) 2016-01-28
US10213405B2 (en) 2019-02-26
US20060106104A1 (en) 2006-05-18
US20160256424A1 (en) 2016-09-08
ES2550616T5 (es) 2022-09-29
BRPI0518173A8 (pt) 2018-01-23
DK2952178T3 (da) 2020-12-07
DK1811959T3 (en) 2015-11-23
NO20072170L (no) 2007-08-15
HK1218620A1 (zh) 2017-03-03
US8569367B2 (en) 2013-10-29
SI2422765T1 (sl) 2015-09-30
US8729125B2 (en) 2014-05-20
US20140045939A1 (en) 2014-02-13
RU2007117637A (ru) 2008-12-27
BRPI0518173B1 (pt) 2020-05-19
HK1107027A1 (zh) 2008-03-28
AR052031A1 (es) 2007-02-28
BRPI0518173B8 (pt) 2021-05-25
US9668997B2 (en) 2017-06-06
WO2006055454A3 (en) 2006-08-03
NO20240132A1 (no) 2007-08-15
EP1811959B2 (en) 2022-06-15
KR20070084264A (ko) 2007-08-24
US20230404961A1 (en) 2023-12-21
WO2006055454A2 (en) 2006-05-26
EP2422765A1 (en) 2012-02-29
TWI369996B (en) 2012-08-11
KR101344602B1 (ko) 2013-12-31
PL383268A1 (pl) 2008-02-18
CA2588044C (en) 2014-05-27
US20140045773A1 (en) 2014-02-13
ES2550616T3 (es) 2015-11-11
PL1811959T3 (pl) 2015-11-30
US20140256675A1 (en) 2014-09-11
AU2012203398B2 (en) 2015-01-15
NO347855B1 (no) 2024-04-22
AU2005306721A1 (en) 2006-05-26
US20130190398A1 (en) 2013-07-25
EP2422765B1 (en) 2015-04-29
EP2952178A1 (en) 2015-12-09
CA2588044A1 (en) 2006-05-26
DK2422765T3 (en) 2015-08-03
BRPI0518173A (pt) 2008-11-04
US20210401789A1 (en) 2021-12-30
DK1811959T4 (da) 2022-06-27
BR122019023144B8 (pt) 2021-07-27
JP2008520671A (ja) 2008-06-19
US20190365692A1 (en) 2019-12-05
JP5179880B2 (ja) 2013-04-10
PT2422765E (pt) 2015-09-16
TW200631605A (en) 2006-09-16
EP1811959A2 (en) 2007-08-01
IL182532A0 (en) 2007-09-20
BR122019023144B1 (pt) 2021-02-09
US20180021282A1 (en) 2018-01-25
CN101056618B (zh) 2015-02-11

Similar Documents

Publication Publication Date Title
CY1116936T1 (el) Οφθαλμικες συνθεσεις και μεθοδοι για τη θεραπευτικη αγωγη των οφθαλμων
CY1105877T1 (el) Οφθαλμικες συνθεσεις πepιεχουσες συνepγιστικο συνδυασμο τριων πολυμepων
NO20081878L (no) Diacylindazolderivater som lipase- og fosfolipaseinhibitorer
CY1115891T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση των διαταραχων του εσω ωτος
NO20065652L (no) Fremgangsmate for fremstilling av formede gjenstander pa basis av tverrbundet gelatin
CY1121865T1 (el) Οφθαλμολογικες συνθεσεις και η χρηση τους
BRPI0516857A (pt) dispositivos biomédicos que contêm copolìmeros de bloco anfifìlico
TW200740416A (en) Corneal onlays and related methods
CR9591A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
NO20050427L (no) Carvedilolfosfatsalter og/eller solvater derav, tilsvarende preparater og/eller behandlingsfremgangsmater
WO2006127987A3 (en) Treatment of eye disorders with sirtuin modulators
NZ592448A (en) Method and apparatus for limiting growth of eye length
WO2003101397A3 (en) Tetravalent dengue vaccines
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
TR200400526T4 (tr) Göz kurumasının tedavisi için lipoksin A4 ve analogları
CY1115617T1 (el) Χρηση της εποθιλονης κατα τη θεραπευτικη αγωγη νοσηματων τα οποια σχετιζονται με την πρωτεϊνη ταu εις τα οποια συμπεριλαμβανεται η νοσος του αlzheimer
DK1933869T3 (da) Anvendelse af IL-23- og IL-17-antagonister til behandling af autoimmun øjenbetændelsessygdom
DE602005026556D1 (de) Zusammensetzung zur proteasomhemmung
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
BRPI0818183A2 (pt) reparo e regeneração do tecido renal usando células derivadas do tecido do cordão umbilical humano
DK2170857T3 (da) 3',4',5-trimethoxyflavonderivater som stimulerende middel ved slimafsondring, tilsvarende fremgangsmåde og farmaceutisk præparat, der indeholder disse
HK1110207A1 (en) Ophthalmic compositions and methods of using the same
BRPI0605526A (pt) sistema de alinhamento de imagem para uso em tratamento de ablação a laser da córnea e métodos associados
TR200201250T2 (tr) Hidroksieikosatetraenoat tuzları, bileşimleri ve bunların göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri.
CY1108809T1 (el) Μεθοδοι κατασκευης 6-[(4.5-διϋδρο-1η-ιμιδαζολ-2-υλ)αμινο-]-7-μεθυλ-1η-βενζιμιδαζολο-4-kapboniτριλιου και προτιμωμενη μορφη αλατος αυτου